Ahead of a very uncertain advisory committee hearing planned for next month, Sarepta Therapeutics shares are getting a bump today on news that the chairman and two other directors bought $2.5 million worth of shares at market price.
Sarepta (Nasdaq: SRPT) shares were up more than 12 percent as of 11 a.m. to $16.41. That’s a few cents shy of the highest point the 200-employee Cambridge-based company’s shares have reached since a January bombshell from the FDA in the form of highly negative briefing documents regarding Sarepta’s data in support of its potential drug for Duchenne muscular dystrophy.
Sarepta (Nasdaq: SRPT) shares were up more than 12 percent as of 11 a.m. to $16.41. That’s a few cents shy of the highest point the 200-employee Cambridge-based company’s shares have reached since a January bombshell from the FDA in the form of highly negative briefing documents regarding Sarepta’s data in support of its potential drug for Duchenne muscular dystrophy.
